Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis (SCALP). This study has been completed. Sponsor:. There is ample evidence of efficacy of the newer systemic therapies ( biologics ); however, cost is a major consideration with these agents. A 52-week open-label study of the safety of calcitriol ointment did not reveal an adverse effect on calcium homeostasis 37. Biologic treatments have revolutionized the management of psoriasis and psoriatic arthritis (PsA). (known as TRANSFIGURE)(NCT01807520); moderate to severe scalp psoriasis (NCT02267135); and PsA (NCT01989468; NCT02294227; NCT01892436), including a 5-year study for PsA (known as FUTURE 2)(NCT01752634). The phase 3 STATURE trial assessed the safety and effectiveness of SC and IV AIN457 in moderate to severe psoriasis in partial AIN457 nonresponders.
Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab. Prot CAIN457AUS01: A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate the efficacy of subcutaneous secukinumab 300 mg as assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 weeks of treatment, compared to placebo, and to assess safety and tolerability up to 24 weeks in adult subjects with moderate to severe scalp psoriasis. Prot R668-AD-1314: A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab. Safety and Efficacy of Adalimumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Results from First 12 Weeks of PIONEER I, a Phase 3, Randomized, Placebo- Controlled Trial. We sought to directly compare efficacy and safety of secukinumab versus ustekinumab. 1:1 to subcutaneous injection of secukinumab 300 mg or ustekinumab per label.
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year. Secukinumab in Adults With Moderate to Severe Scalp Psoriasis. Subjects were treated with subcutaneous secukinumab 300 mg (n 1410; CONCLUSION: APR significantly reduced the severity of moderate-to-severe plaque psoriasis, including nail, scalp, and palmoplantar psoriasis, at Week 16, and improvements were observed up to Week 32. Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis. Condition(s): Chronic Scalp Psoriasis Last Updated: May 4, 2016Completed.
Kenneth B Gordon Grants Northwestern Scholars
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (AURIEL-PsO). This study will assess efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis. A Adults with moderate to severe chronic plaque psoriasis. Additionally, significant improvements were also reported in nail and scalp psoriasis for the 75- and 150-mg dose groups. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years; results from an open-label extension study for patients from REVEAL. Lesions appear on any part of the skin, but particularly the scalp, sacral area, and over the extensor aspect of the knees and elbows. Clinical efficacy and safety of anti-fibrotic treatments (e.g., imatinib) await confirmation. (Stelara) for the treatment of adults with moderate-to-severe psoriasis.